NERV - Minerva Neurosciences, Inc.
| Previous Close | 8.85 |
| Open | 8.70 |
| Bid | 8.55 x 3200 |
| Ask | 8.65 x 1100 |
| Day's Range | 8.50 - 8.80 |
| 52 Week Range | 4.80 - 10.15 |
| Volume | 65,701 |
| Avg. Volume | 169,268 |
| Market Cap | 331.307M |
| Beta | 1.19 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- MarketWatch•last month
Minerva Neurosciences shares rise 5% on trial results for schizophrenia drug
Minerva Neurosciences Inc. shares rose 5.4% in premarket trade on Thursday after results from a phase 2b trial for a schizophrenia drug were published in the peer-reviewed The Journal of Clinical Psychiatry. ...
- Thomson Reuters StreetEvents•2 months ago
Edited Transcript of NERV earnings conference call or presentation 3-May-18 12:30pm GMT
Q1 2018 Minerva Neurosciences Inc Earnings Call
- Associated Press•2 months ago
Minerva Neurosciences: 1Q Earnings Snapshot
On a per-share basis, the Waltham, Massachusetts-based company said it had a loss of 32 cents. Minerva Neurosciences shares have risen 14 percent since the beginning of the year. The stock has fallen nearly ...
- Zacks•3 months ago
Will Minerva Neurosciences (NERV) Continue to Surge Higher?
As of late, it has definitely been a great time to be an investor in Minerva Neurosciences, Inc. (NERV).
- Thomson Reuters StreetEvents•3 months ago
Edited Transcript of NERV earnings conference call or presentation 12-Mar-18 12:30pm GMT
Q4 2017 Minerva Neurosciences Inc Earnings Call
- Associated Press•3 months ago
Minerva Neurosciences posts 4Q profit
The Waltham, Massachusetts-based company said it had net income of less than 1 cent on a per-share basis. Losses, adjusted for pretax gains, were 24 cents per share. For the year, the company reported ...
- Zacks•6 months ago
Minerva Initiates Phase III Study on Schizophrenia Candidate
Minerva Neurosciences (NERV) initiates a phase III study to evaluate MIN-101 as monotherapy to treat negative symptoms in schizophrenia patients.
- Thomson Reuters StreetEvents•8 months ago
Edited Transcript of NERV earnings conference call or presentation 6-Nov-17 1:30pm GMT
Q3 2017 Minerva Neurosciences Inc Earnings Call
- Simply Wall St.•9 months ago
Is Minerva Neurosciences Inc (NERV) Undervalued?
Minerva Neurosciences Inc (NASDAQ:NERV), a pharmaceuticals, biotechnology and life sciences company based in United States, Check out our latest analysis for Minerva Neurosciences What’s the opportunity in NERV? Great newsRead More...
- Zacks•10 months ago
Minerva-J&J's Amendment of MIN-202 Contract Wins EU Approval
The EU approves of Minerva's (NERV) amendment of MIN-202 license agreement with Janssen. Per the deal, Minerva will receive an upfront payment from Janssen.
- TheStreet.com•10 months ago
Adamas Skyrockets on FDA Approval for Dyskinesia Treatment - Biotech Movers
The Emeryville, Calif.-based firm secures FDA approval for Gocovri as a treatment for dyskinesia in Parkinson's disease patients.
- Motley Fool•11 months ago
Why Minerva Neurosciences Inc. Fell 31.1% in July
These two news items were the primary reasons that Minerva's stock shed nearly a third of its value last month.
- Thomson Reuters StreetEvents•10 months ago
Edited Transcript of NERV earnings conference call or presentation 3-Aug-17 12:30pm GMT
Q2 2017 Minerva Neurosciences Inc Earnings Call
- Associated Press•11 months ago
Minerva Neurosciences reports 2Q loss
On a per-share basis, the Waltham, Massachusetts-based company said it had a loss of 27 cents. Minerva Neurosciences shares have fallen 43 percent since the beginning of the year. The stock has dropped ...
- Zacks•last year
Minerva On Track to Initiate Phase III Schizophrenia Study
Minerva Neurosciences, Inc. (NERV) announced that it is on track to begin phase III studies on its key schizophrenia pipeline candidate MIN-101 in the second half of this year, as planned.
